Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.55 |
| ▸ | RELA | Q04206 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18573582 | 0.93 | PTPN1 (0.63) | PTPN1NPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL14479883 | 0.88 | PTPN1 (0.60) | PTPN1NPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL18573578 | 0.81 | HDAC3 (0.53) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL18573537 | 0.80 | NPC1 (0.63) | PTPN1NPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL12789568 | 0.80 | PTPN1 (0.84) | PTPN1NPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL18573589 | 0.78 | RAB9A (0.53) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL31337446 | 0.77 | PTPN1 (0.67) | PTPN1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL23035052 | 0.75 | HDAC1 (0.57) | NPC1RAB9ASMN1; SMN2PKMNFKB1 | |
| SCHEMBL18573643 | 0.74 | RAB9A (0.60) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL18573642 | 0.73 | NPC1 (0.63) | PTPN1NPC1RAB9ASMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3339299-B1 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AUTOPHAGYSCIENCES INC (KR) | 2021-03-03 | — | — | EP | claimed |
| US-20200255397-A1 | METHOD FOR TREATING LIVER DISEASE BY ADMINISTERING PHARMACEUTICAL COMPOSITION COMPRISING CATECHOL DERIVATIVE | Autophagysciences Inc. (KR) | 2020-08-13 | — | — | US | claimed |
| US-20180244644-A1 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Autophagysciences Inc. (KR) | 2018-08-30 | — | — | US | claimed |
| EP-3339299-A2 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Autophagysciences, Inc (KR) | 2018-06-27 | — | — | EP | claimed |
| EP-3339299-B1 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AUTOPHAGYSCIENCES INC (KR) | 2021-03-03 | — | — | EP | disclosed |
| EP-3339299-B1 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AUTOPHAGYSCIENCES INC (KR) | 2021-03-03 | — | — | EP | disclosed |
| CN-107922374-B | Novel catechol derivatives and pharmaceutical compositions containing the same | 自体吞噬科学有限公司 | 2020-11-06 | — | — | CN | disclosed |
| US-20200255397-A1 | METHOD FOR TREATING LIVER DISEASE BY ADMINISTERING PHARMACEUTICAL COMPOSITION COMPRISING CATECHOL DERIVATIVE | Autophagysciences Inc. (KR) | 2020-08-13 | — | — | US | disclosed |
| US-20200255397-A1 | METHOD FOR TREATING LIVER DISEASE BY ADMINISTERING PHARMACEUTICAL COMPOSITION COMPRISING CATECHOL DERIVATIVE | Autophagysciences Inc. (KR) | 2020-08-13 | — | — | US | disclosed |
| US-10662169-B2 | Catechol derivative and pharmaceutical composition comprising the same | Autophagysciences Inc. (KR) | 2020-05-26 | — | — | US | disclosed |
| US-10662169-B2 | Catechol derivative and pharmaceutical composition comprising the same | Autophagysciences Inc. (KR) | 2020-05-26 | — | — | US | disclosed |
| US-20180244644-A1 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Autophagysciences Inc. (KR) | 2018-08-30 | — | — | US | disclosed |
| EP-3339299-A2 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Autophagysciences, Inc (KR) | 2018-06-27 | — | — | EP | disclosed |
| EP-3339299-A2 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Autophagysciences, Inc (KR) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017034242-A2 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 유영제약 | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255397-A1 | METHOD FOR TREATING LIVER DISEASE BY ADMINISTERING PHARMACEUTICAL COMPOSITION COMPRISING CATECHOL DERIVATIVE | ATG7, BECN1, SLC10A1 | PTPN1 2563/4885NPC1 27/4885RAB9A 167/4885 |
| US-10662169-B2 | Catechol derivative and pharmaceutical composition comprising the same | BECN1, ATG7, SQSTM1 | PTPN1 2061/4885NPC1 45/4885RAB9A 197/4885 |
| US-20180244644-A1 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | BECN1, ATG7, TFEB | PTPN1 2195/4885NPC1 40/4885RAB9A 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.